GOLMAITA
LIVE

Serial Number

98716503

Owner

Celgene Corporation

Attorney

Marilyn F. Kelly

Filing Date

Aug 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GOLMAITA Trademark

Serial Number: 98716503

GOLMAITA is a trademark filed by Celgene Corporation on August 26, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

August 26, 2024

Registration Date

Not Registered

Published for Opposition

November 25, 2025

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 20, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 25, 2025 NPUB
PUBLISHED FOR OPPOSITION
Nov 25, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 19, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 27, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Oct 27, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Oct 27, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Oct 27, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Oct 27, 2025 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 12, 2025 GNFN
FINAL REFUSAL E-MAILED
Jul 12, 2025 GNFR
FINAL REFUSAL WRITTEN
Jul 12, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 9, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 9, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 9, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 8, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 8, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 8, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 8, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 7, 2025 NWOS
NEW APPLICATION ENTERED
Aug 26, 2024 NWAP